Ligia Carolina Facin: Investigating a Novel Therapeutic Strategy for ATTR-CM
Ligia Carolina Facin, Fellowship in Cardiac Amyloidosis at Ensino InCor, Cardio-Oncology Resident at Heart Institute, University of São Paulo (FMUSP), shared a post on LinkedIn:
“It was a great privilege to participate in the CLEOPATTRA Investigators’ Meeting, an international clinical trial investigating a novel therapeutic strategy for transthyretin amyloid cardiomyopathy (ATTR-CM).
Over the past few years, we have witnessed remarkable advances in the treatment of ATTR-CM.
Now, a new frontier is being explored: therapies aimed at removing amyloid deposits already present in cardiac tissue, with the potential to further transform the course of the disease.
Being part of a study investigating this innovative therapeutic approach is a unique opportunity to contribute to the evidence that may shape the future of cardiac amyloidosis treatment.
Science, international collaboration, and clinical research opening new perspectives for our patients.”
Stay updated with Hemostasis Today.
-
Oct 5, 2026, 10:45Mohammed Ayaz Ali։ HIT – When an Anticoagulant Causes Thrombosis
-
Oct 5, 2026, 10:24Vishnu Priya Pulipati: The Endocrinologist’s Role in Lp(a) and Cardiovascular Risk Reduction
-
Oct 5, 2026, 09:59William McKeown – A Busy Week with the European Haemophilia Consortium
-
Oct 5, 2026, 09:46Megan Buchholz – Celebrating Apheresis Awareness Day 2026 at St. Michael’s Hospital
-
Oct 5, 2026, 09:34ITP Myth vs. Fact – A Common Misconception – ITP Support Association
-
Oct 5, 2026, 09:20Jan Sloves: Medial Thigh Venous Perforators – Why Diameter Isn’t the Whole Story
-
Oct 5, 2026, 09:16Emmanuele Kouvousis: ASH Sets New Standards for Diagnosing Iron Deficiency
-
Oct 5, 2026, 09:12Arun V J: Fresh Whole Blood vs Evidence-Based Transfusion
-
Oct 5, 2026, 09:06Edward Lee Carter: NOTION-4 – HALT and Clinical Outcomes